NasdaqCM - Nasdaq Real Time Price USD

Bionano Genomics, Inc. (BNGO)

Compare
0.4390 +0.0073 (+1.69%)
At close: October 3 at 4:00 PM EDT
0.4385 -0.00 (-0.11%)
After hours: October 3 at 7:56 PM EDT
Loading Chart for BNGO
DELL
  • Previous Close 0.4317
  • Open 0.4280
  • Bid 0.3079 x 200
  • Ask 0.5616 x 200
  • Day's Range 0.4229 - 0.4470
  • 52 Week Range 0.3100 - 3.0100
  • Volume 888,510
  • Avg. Volume 1,735,953
  • Market Cap (intraday) 37.753M
  • Beta (5Y Monthly) 2.33
  • PE Ratio (TTM) 0.04
  • EPS (TTM) 9.8900
  • Earnings Date Nov 6, 2024 - Nov 11, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 1.90

Bionano Genomics, Inc. provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA. The company also provides Saphyr and Bionano compute servers; and VIA software, which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; OGM-Dx HemeOne testing; OGM-Dx FSHD, a test for individuals suspected of having FSHD type 1; and OGM-Dx Postnatal Whole Genome SV and OGM-Dx Prenatal Whole Genome SV for comprehensive testing. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.

www.bionano.com

344

Full Time Employees

December 31

Fiscal Year Ends

Recent News: BNGO

View More

Performance Overview: BNGO

Trailing total returns as of 10/3/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

BNGO
76.77%
S&P 500
19.50%

1-Year Return

BNGO
85.02%
S&P 500
32.92%

3-Year Return

BNGO
99.16%
S&P 500
30.82%

5-Year Return

BNGO
92.92%
S&P 500
97.39%

Compare To: BNGO

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: BNGO

View More

Valuation Measures

Annual
As of 10/3/2024
  • Market Cap

    37.73M

  • Enterprise Value

    46.36M

  • Trailing P/E

    0.04

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.43

  • Price/Book (mrq)

    0.47

  • Enterprise Value/Revenue

    1.27

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -32.64%

  • Return on Equity (ttm)

    -138.33%

  • Revenue (ttm)

    36.58M

  • Net Income Avi to Common (ttm)

    -204.1M

  • Diluted EPS (ttm)

    9.8900

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    18.94M

  • Total Debt/Equity (mrq)

    34.32%

  • Levered Free Cash Flow (ttm)

    -55.98M

Research Analysis: BNGO

View More

Company Insights: BNGO

Research Reports: BNGO

View More

People Also Watch